VKTX vs XENE Stock Comparison

XENE currently leads VKTX in this stock comparison, with AIQ scores of 49 vs 41. The clearest difference is quality, while VKTX has the stronger momentum profile.

Market data as of Nov 15, 2026 market close· AIQ score gap 8 points
VKTX
Healthcare
vs
XENE
Healthcare
VKTX
Viking Therapeutics, Inc.
Price
$29.22
Day move
+5.95%
AIQ Score
41/100
Best edge
Momentum
Sector
Healthcare
XENE
Xenon Pharmaceuticals Inc.
Leads
Price
$40.48
Day move
-1.26%
AIQ Score
49/100
Best edge
Quality
Sector
Healthcare

What is the main difference between VKTX and XENE?

XENE leads the current stock comparison as Xenon Pharmaceuticals Inc., with the clearest separation coming from quality and the broader AIQ evidence mix.

AlgovestIQ AIQ Comparison

Viking Therapeutics, Inc. vs Xenon Pharmaceuticals Inc.

Data as of Nov 15, 2026· market close· Healthcare· Coverage 62/66 fields· High confidence
AIQ VerdictFragileAIQ Comparison Conviction 4/10

XENE leads

XENE leads by 8 AIQ points, primarily on Quality and Risk Resilience, but the lead has narrowed from 11 points over 30 sessions. Wall Street currently favors VKTX on target upside.

Fragile: 3 of 5 evidence groups support XENE, and its lead is narrowing.

Evidence agreement: 3 of 5Comparison trend: Weakening
VKTX

Viking Therapeutics, Inc.

AIQ Score
41/100
AIQ Edge Score
7/10
XENE

Xenon Pharmaceuticals Inc.

Leads
AIQ Score
49/100
AIQ Edge Score
8/10

The Algovestiq AIQ Score currently favors XENE over VKTX, 49 versus 41 as of Nov 15, 2026. XENE's advantage is driven primarily by stronger quality and risk resilience, while VKTX holds the stronger momentum profile. XENE also shows the weaker technical structure relative to its 50-day moving average, though analyst target upside currently favors VKTX. 3 of 5 covered evidence groups favor XENE today, and the comparison is rated Fragile on stability: the leader's advantage has been narrowing. XENE lead: Weakening — the AIQ differential moved from 11 to 8 points over 30 sessions.

Compare Viking Therapeutics, Inc. and Xenon Pharmaceuticals Inc. across the Algovestiq AIQ Score, valuation, quality, momentum, risk, technicals and analyst expectations.

Currently unavailable

Performance over time

Price return from daily closes; distributions are not included.

VKTX
+404.7%
XENE
+32.2%

Price return comparison

Growth of $10,000, price only

VKTX $50,466 · XENE $13,216

Split-adjusted closes only. Distributions are excluded, which understates the return of any fund or stock that pays them.

Compare VKTX and XENE against another ticker

Open a multi-ticker workspace without changing this focused pair page.

Basic: 2 symbols·Explorer: 3 symbols·Pro and Premium: 5 symbols·Your limit: 2

AIQ Factor Divergence

Where the two separate, on the four dimensions behind the AIQ Score. Bars read outward from a shared zero: further from the centre is a wider gap.

VKTX advantage
0
XENE advantage
  • Quality33 vs 68
    XENE +35
  • Momentum47 vs 33
    VKTX +14
  • Risk Resilience41 vs 49
    XENE +8

3 of 5 evidence groups favor XENE. XENE’s edge is concentrated in quality and risk resilience; VKTX keeps a meaningful momentum edge.

What changed since the last close

Latest scored session 2026-11-13, compared against the prior scored session 2026-11-12.

VKTX+2 AIQ

Largest factor move: Momentum +3

New signals

  • Accumulation Pattern — bullish, volume, medium horizon (2.11x)
  • MACD Histogram Expanding Bullish — bullish, momentum, short horizon
  • RSI Midline Reclaim — bullish, momentum, short horizon
XENE0 AIQ

Largest factor move: Quality +1, not enough on its own to move the overall score.

New signals

  • ADX Trend Weakening — neutral, trend, medium horizon
  • Low Volume Rally Warning — bearish, volume, short horizon (0.47x)

XENE's lead narrowed by 2 AIQ points in the latest session.

Deeper signal detail for each name lives on its own signals page — VKTX and XENE both carry a full feed there.

The central trade-off

XENE (Xenon Pharmaceuticals Inc.): the stronger current systematic profile, led by quality and risk resilience.

VKTX (Viking Therapeutics, Inc.): the counter-case, on momentum, technicals, analyst expectations — but at materially higher volatility, 69.7% against 38%.

The AIQ Score and Wall Street therefore point in different directions on this pair.

Which one fits your objective

The same two names rank differently depending on what you are optimizing for. All six reads are shown at once — none of them is hidden behind a toggle.

Balanced

XENE

XENE on the overall AIQ Score, which weights Quality and Value most heavily.

Growth

XENE

XENE on combined revenue and EPS growth.

Value

Even

The two are level on Value.

Momentum

VKTX

VKTX on the Momentum factor, by 14 points.

Lower downside

XENE

XENE on Risk Resilience, by 8 points.

Analyst upside

VKTX

VKTX on implied upside to the consensus price target.

AIQ vs Wall Street

The model and the Street disagree here: AIQ favors XENE, analyst targets favor VKTX. That disagreement is the most useful thing on this page.

MeasureVKTXXENENote
Implied upside to target+172.6%+67.6%VKTX has more room
Target dispersion+107.9%+64.8%Lower is tighter analyst agreement
ConsensusBuyBuyContext, not a primary driver
Analysts covering2118Higher coverage generally improves confidence

The two are measuring different things. The AIQ Score reads current fundamentals, valuation, trend and risk; analyst targets price forward expectations. A divergence of this kind is either a contrarian opportunity or a sign the model is missing something already priced in — it is worth resolving before acting on either.

Analyst targets are expectations, not predictions. Dispersion matters as much as the midpoint.

AIQ Agreement Matrix

3 of 5 covered evidence groups favor XENE. A wide gap backed by one group is a weaker case than a narrow gap backed by five.

Evidence groupFavorsReading
AIQ ScoreXENE41 vs 49
FundamentalsXENErevenue growth 0% vs 0%; TTM ROE -31.1% vs -9.6%; gross margin 0% vs 0%; operating margin 0% vs 0%
ValuationNot coveredNot covered
TechnicalsVKTXPrice vs 50-day -0.4% vs -1.6%; vs 200-day -9.2% vs -22.6%
Risk ResilienceXENERisk Resilience 41 vs 49
Analyst expectationsVKTXTarget upside 172.6% vs 67.6%

✓ agrees with the overall verdict · ✕ points the other way. Groups marked “not covered” lack data on one or both of VKTX and XENE and are excluded from the count.

AIQ Decision Stability

Fragile

The conclusion is sensitive to small changes. Treat the lead as provisional and watch the flip conditions below.

  • The AIQ gap is moderate at 8 points.
  • The leader's advantage has been narrowing. (argues the conclusion is provisional)
  • The lead has been steady session to session. (supports the conclusion holding)
  • Signal direction runs against the verdict: the leader is net-bearish while the laggard is net-bullish. (argues the conclusion is provisional)
  • Analyst targets on the leader are widely dispersed. (argues the conclusion is provisional)

Stability combines the score gap, how broadly the evidence agrees, how steady the lead has been across daily snapshots, the current signal state on both names, and analyst dispersion on XENE.

How the comparison changed

120 daily snapshots · May 27 – Nov 13

XENE lead: Weakening — the AIQ differential moved from 11 to 8 points over 30 sessions.

May 27VKTX leads above the line · XENE leads belowNov 13
Today
XENE +8
41 vs 49
7 sessions ago
XENE +10
39 vs 49
30 sessions ago
XENE +11
35 vs 46
90 sessions ago
XENE +24
49 vs 73

The lead changed hands 2 times in this window, most recently on Oct 1 when XENE moved ahead of VKTX.

AIQ Signal Divergence

Only the signals that bear on the head-to-head. A conflicted name is carrying bullish and bearish rules at the same time — the technical evidence is not pointing one way.

VKTXConflicted

4 bullish / 3 bearish / 1 neutral, conflicted

Only VKTX

  • Accumulation Pattern — bullish, volume, medium horizon (2.11x)
  • Beta Spike Warning — bearish, risk_regime, long horizon
  • MACD Histogram Expanding Bullish — bullish, momentum, short horizon
  • RSI Midline Reclaim — bullish, momentum, short horizon
  • Volume Surge - Bullish — bullish, volume, short horizon (2.11x)
XENE

0 bullish / 3 bearish / 2 neutral

Only XENE

  • ADX Trend Weakening — neutral, trend, medium horizon
  • Low Volume Rally Warning — bearish, volume, short horizon (0.47x)

Both carry 3 more signals that do not separate them: Death Cross Active, ATR Expansion - Breakout Mode, Downtrend Structure Active.

VKTX is conflicted, so the timing case there is weaker than the score alone suggests.

Price vs model alignment

Whether the latest session's price move confirms what the model did over the same session, or contradicts it.

VKTXConfirmed strength

Price and the AIQ Score both moved up over the latest session (price +5.95%, AIQ +2 points).

XENENo material change

Neither the price nor the AIQ Score moved enough in the latest session to confirm or contradict the other (price -1.26%, AIQ 0 points).

What would flip this result

A state, not a forecast. These are the specific, observable changes that would reverse the verdict — not a price prediction.

  1. 1VKTX closes the Quality gap — currently 35 points behind, the largest single contributor to XENE's edge.
  2. 2VKTX's Death Cross Active resolves — a bearish trend rule currently active against it.
  3. 3XENE starts generating bearish momentum or trend signals.
  4. 4The narrowing continues — the lead has already given back 3 points over 30 sessions, and a further 8-point move would eliminate XENE's advantage entirely.

The full evidence

Every number behind the verdict. The leader is called above each group so you are not left to solve it from the table.

Fundamentals

XENE leads on balance
MetricVKTXXENE
Revenue growth (YoY)0%0%
EPS growth (YoY)-40.9%0%
Gross margin0%0%
Operating margin0%0%
Return on equity (TTM)-31.1%-9.6%
Debt to equity0.430.01

Performance

Split across windows
MetricVKTXXENE
1 week (5 sessions)8.9%3.3%
1 month (20 sessions)16.1%20.9%
3 months (63 sessions)-13.1%-35.1%
6 months (126 sessions)-3.5%-25.6%
Year to date-16.9%-9.7%
1 year (252 sessions)-28.3%2%

Technicals

VKTX has the stronger structure
MetricVKTXXENE
RSI (14)5554.9
ADX (14)13.724
Price vs 50-day-0.4%-1.6%
Price vs 200-day-9.2%-22.6%
Volatility (1M, annualized)69.7%38%

Risk

XENE is the more resilient
MetricVKTXXENE
Beta1.290.86
Sharpe ratio-0.150.27
Sortino ratio-0.250.48
Max drawdown-42.5%-52.8%
Current drawdown-30.6%-43%
Annualized volatility69.2%68.1%
Value at risk (95%)-5.6%-3.3%

Straight answers

Each answer is regenerated from the current snapshot, not written once and left to age.

Which is better, VKTX or XENE?

On the Algovestiq AIQ Score, XENE is the stronger of the two as of Nov 15, 2026, scoring 49 against VKTX's 41. The edge comes from quality and risk resilience. VKTX is not without a case — it holds the better momentum profile, which matters more if that is the objective you are optimizing for. This is a systematic score, not a recommendation: it ranks the two on the same evidence, it does not know your holding period or tax position.

Is VKTX or XENE the better buy right now?

XENE carries the stronger systematic profile as of Nov 15, 2026, and the comparison is rated Fragile — 3 of 5 covered evidence groups agree. A Fragile rating means the conclusion is sensitive: the leader's advantage has been narrowing. Treat the lead as provisional.

Why does the AIQ Score favor XENE over VKTX?

The composite weights Quality, Value, Momentum and Risk Resilience. XENE leads Quality by 35 points; VKTX leads Momentum by 14 points; XENE leads Risk Resilience by 8 points. Where the two split, the factor with the larger weight carries the result.

Which has more analyst upside, VKTX or XENE?

Analyst price targets imply +172.6% upside for VKTX and +67.6% for XENE, so the Street currently favors VKTX. That points the opposite way to the AIQ Score, which favors XENE. The two are measuring different things: the model reads current fundamentals, valuation, trend and risk; the Street is pricing forward expectations. A divergence of this kind is either a contrarian opportunity or a sign the model is missing something the analysts have already priced — it is the single most useful row on this page to investigate. Analyst targets are expectations, not predictions, and dispersion matters as much as the midpoint.

Which is better value, VKTX or XENE?

Neither name separates on the peer-relative Value factor. The two are level on Value. The Value factor reads valuation relative to sector peers and to the company's own fundamental quality, so it is not the same as simply having the lower multiple.

Which has stronger growth, VKTX or XENE?

XENE on combined revenue and EPS growth. Growth here is measured on reported revenue and earnings, not on forward estimates — it describes what the businesses have delivered, not what the Street expects next.

Which has stronger momentum, VKTX or XENE?

VKTX on the Momentum factor, by 14 points. Momentum is one of the four weighted factors in the AIQ composite. It has documented persistence over three- to twelve-month horizons, which makes it a timing input rather than a reason to hold something indefinitely.

Which is riskier, VKTX or XENE?

XENE is the more resilient of the two, so the other name carries the higher downside risk. XENE on Risk Resilience, by 8 points. Risk Resilience is a weighted factor in the composite; position sizing usually responds to it more usefully than the buy/avoid decision does.

Is VKTX more profitable than XENE?

XENE leads on the comparable margin measures — gross margin 0% vs 0%; operating margin 0% vs 0%; ttm roe -31.1% vs -9.6%.

Is XENE's lead over VKTX getting stronger or weaker?

XENE lead: Weakening — the AIQ differential moved from 11 to 8 points over 30 sessions. This is measured from 120 daily comparison snapshots between 2026-05-27 and 2026-11-13. The lead has changed hands 2 times in that window, most recently on 2026-10-01, when XENE moved ahead of VKTX.

What would change the VKTX vs XENE verdict?

The result is a state, not a forecast, so it changes when the underlying evidence changes. Concretely: VKTX closes the Quality gap — currently 35 points behind, the largest single contributor to XENE's edge; VKTX's Death Cross Active resolves — a bearish trend rule currently active against it; XENE starts generating bearish momentum or trend signals; the narrowing continues — the lead has already given back 3 points over 30 sessions, and a further 8-point move would eliminate XENE's advantage entirely.

What do the current signals say about VKTX and XENE?

VKTX: 4 bullish / 3 bearish / 1 neutral, conflicted. XENE: 0 bullish / 3 bearish / 2 neutral. A conflicted state means bullish and bearish rules are active on the same name at once — the technical evidence is not pointing one way, and a decision taken on it carries more timing risk. The most decision-relevant rule on VKTX is Death Cross Active (bearish, long horizon). On XENE it is Death Cross Active (bearish, long horizon).

Compare VKTX and XENE with others

Continue your research

This page answers which of the two. These answer the questions on either side of it.

How this comparison is scored

The Algovestiq AIQ Score composites four factors — Quality, Value, Momentum and Risk, each carrying a fixed weight. Sentiment is reported separately as SentimentPulse and is not folded into the composite. Scores refresh every trading day, and this page regenerates from the latest snapshot rather than being written once.

The verdict names a leader, states how broadly six independent evidence groups agree, and rates how durable that conclusion is given the score gap, its recent trajectory and the current signal state on both names.

How to use side-by-side comparison →

This comparison is informational and educational, not investment advice. AIQ scores update daily; re-check after earnings, guidance or macro data that materially changes either name’s factor profile.